The Executive Committee on Global Health and Human Security has compiled draft proposals to further promote pharmaceutical and medical device regulatory harmonization in Asia. While the proposals revolve around initiatives for two main pillars - building clinical trial networks and…
HOME > TRENDS
TRENDS
-
51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases
December 27, 2019
-
Top 10 PHARMA JAPAN Articles in 2019
December 26, 2019
-
Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
August 30, 2019
-
Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
-
Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
-
Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
-
Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
-
12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
-
Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
June 18, 2019
-
Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
May 28, 2019
-
Cancer Drugs Underpin Big Pharmas’ Japan Revenue in 2018
April 25, 2019
-
Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter
March 5, 2019
-
Industry Workforce Dwindling as More and More Staffers Take Voluntary Retirement; Astellas Could Cut 700 Jobs
February 22, 2019
-
Rituxan Biosimilar Grabs 30% Volume Share in Just 1 Year; Sales Expected to Double in 2019
February 12, 2019
-
Drug Formulary Initiatives Moving Beyond Hospitals, Generic Makers Prepping for Regional Lists
January 30, 2019
-
Top 10 PHARMA JAPAN Stories in 2018
December 26, 2018
-
Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
November 28, 2018
-
Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
November 15, 2018
-
Hep C Market Shrinking towards Disease Elimination in 2030
October 12, 2018
-
“Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
September 4, 2018
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…